Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5067660 | 0.94 | ALDH1A1 (0.41) | ALDH1A1HSD11B1EPAS1 | |
| SCHEMBL17795909 | 0.91 | ALDH1A1 (0.44) | ALDH1A1HSD11B1EPAS1 | |
| SCHEMBL2990890 | 0.89 | ALDH1A1 (0.44) | ALDH1A1HSD11B1EPAS1 | |
| SCHEMBL3971196 | 0.88 | ALDH1A1 (0.34) | ALDH1A1EPAS1 | |
| SCHEMBL27327414 | 0.88 | ALDH1A1 (0.41) | ALDH1A1HSD11B1EPAS1 | |
| SCHEMBL28898566 | 0.88 | ALDH1A1 (0.47) | ALDH1A1HSD11B1 | |
| SCHEMBL31273013 | 0.85 | ALDH1A1 (0.35) | ALDH1A1EPAS1 | |
| SCHEMBL6689602 | 0.85 | ALDH1A1 (0.44) | ALDH1A1HSD11B1EPAS1 | |
| SCHEMBL1154960 | 0.85 | ALDH1A1 (0.44) | ALDH1A1HSD11B1EPAS1 | |
| SCHEMBL212308 | 0.85 | ALDH1A1 (0.50) | ALDH1A1HSD11B1EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7847119-B2 | Drug conjugates | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-12-07 | — | — | US | disclosed |
| US-20080139815-A1 | DRUG CONJUGATES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-06-12 | — | — | US | disclosed |
| US-7282590-B2 | Selectively target tumor cells with highly potent cytotoxic drugs at a drug release rate that is effective for the destruction and/or inhibition of tumor cells | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2007-10-16 | — | — | US | disclosed |
| EP-1718335-A2 | DRUG CONJUGATES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-11-08 | — | — | EP | disclosed |
| US-20050232928-A1 | Drug conjugates | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-10-20 | — | — | US | disclosed |
| WO-2005079398-A2 | DRUG CONJUGATES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050232928-A1 | Drug conjugates | RXRB, NR0B1, RXRA | ALDH1A1 399/4885HSD11B1 149/4885EPAS1 3419/4885 |
| US-20080139815-A1 | DRUG CONJUGATES | RXRB, NR0B1, RXRA | ALDH1A1 414/4885HSD11B1 150/4885EPAS1 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.